Abstract 34P
Background
Resilience to stress is a central phenotype underlying cancer cell biology. Cancer resilience empowers cell growth and survival in the face of harsh microenvironments, cytotoxic therapies, and loss of normal cellular regulatory processes. By understanding the mechanisms underlying cancer cell resilience, we may develop therapies which constrain tumors generally or synergize with existing drugs. Here, we sought to identify yet-unknown mechanisms by which cancer cells orchestrate resilience.
Methods
Using genome-scale CRISPR-Cas9 screening data from over 700 unique cancer cell lines (DepMap project), we developed a guilt-by-association “coessentiality” approach to identify genes involved cellular stress response signaling. We then used a combination of molecular biology, evolutionary biology, and computational biology approaches to validate predictions.
Results
Using an unbiased functional genomic approach and subsequent molecular validation, we identified HAPSTR1 (formerly: C16orf72) as a gene which becomes particularly important to cancer cells under stress conditions (e.g., DNA damage, protein aggregation, nutrient starvation). HAPSTR1, despite conservation through worms, yeast, and plants, had no known function. We found that HAPSTR1 encodes a dimeric protein which enables nuclear localization of HUWE1, an otherwise cytoplasmic ubiquitin ligase. Additionally, we show that mammals have a second HAPSTR gene, HAPSTR2 (formerly: RP11-364B14.3), which formed via an atypical evolutionary mechanism and functions to buffer the HAPSTR-HUWE1 pathway in specific cancer subsets.
Conclusions
Altogether, we present a new gene family and biochemical pathway leveraged by cancer cells to empower resilience. Disruption of this pathway broadly impairs stress response regulation and may thus be relevant to understanding and targeting resilience in human tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Institutes of Health (NIH-USA).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
84P - Advancing precision oncology: Integrating immune landscape and genomics for tailored therapy in metastatic cancer patients
Presenter: Eurydice Angeli
Session: Poster session 07
85P - True single-circulating tumor cell genomics reveals enriched therapy-resistance signatures in advanced colorectal cancer patients
Presenter: Manoj Dongare
Session: Poster session 07
Resources:
Abstract
86P - Making the precision oncology landscape of Europe and the Republic of Ireland programmatically accessible
Presenter: Brendan Reardon
Session: Poster session 07
87P - Application of tissue and liquid-based next generation sequencing (NGS) for comprehensive genomic profiling: Evaluating the clinical value of ctDNA technology in treatment decision making
Presenter: Fatima Usman
Session: Poster session 07
88P - Next-generation sequencing (NGS) in routine care: Medical practice in 24 countries from the pan-cancer WAYFIND-R registry
Presenter: Christophe Le Tourneau
Session: Poster session 07
89P - Comprehensive genomic profiling of circulating tumor DNA for treatment recommendation: A sub-project of the IMPRESS-Norway trial
Presenter: Ingrid Dyvik
Session: Poster session 07
90P - Clonal haematopoiesis of indeterminate potential (CHIP) might mislead interpretation of ATM and CHEK2 alterations detected on liquid biopsies
Presenter: Pasquale Rescigno
Session: Poster session 07
91P - Ultra-sensitive ctDNA NGS assay enhances genomic profiling for advanced HR-positive, HER2-negative breast cancer on endocrine therapy
Presenter: Hao Liao
Session: Poster session 07
92P - Transformative diagnostics in urothelial carcinoma: Utilizing targeted NGS and LP-WGS for non-invasive detection and personalized medicine
Presenter: Huan Zhao
Session: Poster session 07
93P - UriMee: A novel non-invasive test for diagnosis of urothelial carcinoma by detection of methylation markers in urinary sediment DNA
Presenter: Ming cao
Session: Poster session 07